中国医药导报2024,Vol.21Issue(10) :98-102.DOI:10.20047/j.issn1673-7210.2024.10.22

泄浊化瘀颗粒配合双歧杆菌四联活菌片治疗高尿酸血症的临床效果

Clinical effect of Xiezhuo Huayu Granules combined with Bifidobacterium Tetra vaccine Tablets in the treatment of hyperuricemia

施丽娜 单红梅 姚志华
中国医药导报2024,Vol.21Issue(10) :98-102.DOI:10.20047/j.issn1673-7210.2024.10.22

泄浊化瘀颗粒配合双歧杆菌四联活菌片治疗高尿酸血症的临床效果

Clinical effect of Xiezhuo Huayu Granules combined with Bifidobacterium Tetra vaccine Tablets in the treatment of hyperuricemia

施丽娜 1单红梅 1姚志华1
扫码查看

作者信息

  • 1. 江苏省常州市武进中医医院治未病科,江苏常州 213000
  • 折叠

摘要

目的 探究泄浊化瘀颗粒配合双歧杆菌四联活菌片治疗高尿酸血症(HUA)的临床效果.方法 选取2021年11月至2023年5月江苏省常州市武进中医医院诊治的HUA患者150例作为研究对象,采用随机数字表法将其分为西医组、中医组、联合组,每组50例.西医组予以双歧杆菌四联活菌片治疗,中医组予以中药泄浊化瘀颗粒治疗,联合组予以双歧杆菌四联活菌片和中药泄浊化瘀颗粒联合治疗.患者共用药6周.比较三组疗效、中医体征、血尿酸(UA)水平、肝肾功能指标及用药安全性.结果 联合组临床疗效优于西医组、中医组(P<0.05).治疗后,联合组和中医组平和质得分较治疗前升高,痰湿质、湿热质、血瘀质得分较治疗前降低(P<0.05),联合组平和质得分高于西医组,痰湿质、湿热质、血瘀质得分较西医组降低(P<0.05),联合组与中医组中医体质得分比较,差异无统计学意义(P>0.05).治疗后,三组UA水平均较治疗前降低,且联合组低于西医组和中医组(P<0.05).三组治疗前后丙氨酸转氨酶、天冬氨酸转氨酶、血尿素氮、血肌酐水平比较,差异无统计学意义(P>0.05).三组在治疗期间均未出现药物不良反应.结论 泄浊化瘀颗粒配合双歧杆菌四联活菌片用于HUA,可有效降低UA水平,改善中医体征,提升疗效,同时不会影响患者肝肾功能,用药安全.

Abstract

Objective To investigate the clinical effect of Xiezhuo Huayu Granules combined with Bifidobacterium Tetravaccine Tablets in the treatment of hyperuricemia(HUA).Methods A total of 150 patients with HUA diagnosed and treated in Wujin Hospital of Traditional Chinese Medicine,Jiangsu Province from November 2021 to May 2023 were selected as the study objects,and they were divided into the western medicine group,the traditional Chinese medicine group,and the combined group by random number table method,with 50 cases in each group.The western medicine group was treated with Bifidobacterium Tetravaccine Tablets,the traditional Chinese medicine group was treated with Chinese medicine Xiezhuo Huayu Granules,and the combined group was treated with Bifidobacter ium Tetravaccine Tablets and Chinese medicine Xiezhuo Huayu Granules.Patients were treated for a total of six weeks.The efficacy,traditional Chinese medicine signs,serum uric acid(UA)level,liver and kidney function indexes,and drug safety were compared among the three groups.Results The clinical effect of the combined group was better than that of the western medicine group and the traditional Chinese medicine group(P<0.05).After treatment,the scores of balanced constitution in the combined group and the traditional Chinese medicine group were higher than before treatment,and the scores of phlegm-dampness constitution,moist-heat constitution,and blood-stasis constitution in the combined group and the traditional Chinese medicine group were lower than before treatment(P<0.05).The scores of balanced constitution in the combined group were higher than those in the western medicine group,and the scores of phlegm-dampness constitution,moist-heat constitution,and blood-stasis constitution in the combined group were lower than those in the western medicine group(P<0.05).There was no significant difference in traditional Chinese medicine physique scores between the combined group and the traditional Chinese medicine group(P>0.05).After treatment,the UA level in the three groups was lower than that before treatment,and the combined group was lower than that in the western medicine group and traditional Chinese medicine group(P<0.05).There was no significant difference in the levels of alanine transaminase,aspartate transaminasee,blood urea nitrogen,and blood creatinine among the three groups before and after treatment(P>0.05).There were no adverse drug reactions in the three groups during treatment.Conclusion Xiezhuo Huayu Granules combined with Bifidobacterium Tetravaccine Tablets for HUA can effectively reduce UA level,improve traditional Chinese medicine signs,and enhance curative effect,while not affecting the liver and kidney function of patients,and the drug is safe.

关键词

高尿酸血症/生活方式干预/泄浊化瘀颗粒/双歧杆菌四联活菌片

Key words

Hyperuricemia/Lifestyle intervention/Xiezhuo Huayu Granules/Bifidobacterium Tetravaccine Tablets

引用本文复制引用

基金项目

江苏省高等学校自然科学面上项目(18KJB350005)

江苏省常州市武进区科技支撑计划(社会发展)项目(WS202110)

出版年

2024
中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
参考文献量26
段落导航相关论文